Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer

• Published in: Cancer science Vol. 109; no. 9; pp. 2841 - 2851
• Main Authors: Dong, Dong, Jia, Li, Zhang, Lufang, Ma, Na, Zhang, Aimin, Zhou, Yunli, Ren, Li
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.09.2018; John Wiley and Sons Inc
• Subjects: Adenocarcinoma; Aged; Antigens; Antigens, Tumor-Associated, Carbohydrate - blood; Benign; biomarker panel; Biomarkers; Biomarkers, Tumor - blood; CA-19-9 Antigen - blood; CA19.9; CA242; Carbohydrates; Carcinoembryonic antigen; Carcinoembryonic Antigen - blood; Carcinoma, Pancreatic Ductal - blood; Carcinoma, Pancreatic Ductal - diagnosis; Carcinoma, Pancreatic Ductal - pathology; Cell Adhesion Molecules - blood; Disease; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Metastasis; Middle Aged; Original; Pancreatic cancer; Pancreatic diseases; pancreatic ductal adenocarcinoma; Pancreatic Neoplasms; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - pathology; periostin; Surveillance; Tumors; CA242; periostin; biomarker panel; CA19.9; pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with few biomarkers to guide treatment options. Carbohydrate antigen 19.9 (CA19.9), the most frequently used biomarker for PDAC, is not sensitive and specific enough for the detection of the disease. This study aimed to evaluate ser...